Current issues of ACP Journal Club are published in Annals of Internal Medicine


Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis


ACP J Club. 2002 May-Jun;136:95. doi:10.7326/ACPJC-2002-136-3-095

Source Citation

Richter JE, Kahrilas PJ, Sontag SJ, et al. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. Am J Gastroenterol. 2001 Nov;96:3089-98. [PubMed ID: 11721754] (All 2002 articles were reviewed for relevancy, and abstracts were last revised in 2008.)



In patients with erosive esophagitis, is lansoprazole better than omeprazole for relieving heartburn?


Randomized {allocation concealed*}†, blinded {patients, clinicians, data collectors, outcome assessors, and data safety and monitoring committee}†,* controlled trial with 8-week follow-up.


162 clinical centers in the United States.


3510 patients who were ≥ 18 years of age (mean age 47 y, 57% men), had endoscopically confirmed erosive esophagitis ≥ grade 2, and had had ≥ 1 episode of moderate-to-very-severe heartburn during the previous 3 days or nights, or both. Exclusion criteria included duodenal or gastric ulcers ≥ 3 mm in diameter; systemic disease affecting the esophagus; history of gastrointestinal bleeding or gastric, duodenal, or esophageal surgery; and long-term use of ulcerogenic drugs. 96% of patients completed the study.


Patients were allocated to lansoprazole, 30 mg (n = 1754), or omeprazole, 20 mg (n = 1756), once daily before breakfast for 8 weeks.

Main outcome measures

Presence and severity (none [score 0] to very severe [score 4]) of daytime and nighttime heartburn, which were recorded in daily diaries.

Main results

More patients in the lansoprazole group than in the omeprazole group had no episodes of heartburn throughout the treatment period ({14% vs 11%}†P < 0.05) and were free of heartburn on day 1 (33% vs 25%, P≤ 0.001). The lansoprazole group had a greater percentage of heartburn-free days (mean 66% vs 62% of days, P < 0.001) and heartburn-free nights (mean 69% vs 64% of nights, P < 0.001) than did the omeprazole group during week 1. Severity of heartburn was lower in the lansoprazole group than in the omeprazole group during the day (mean severity score 0.46 vs 0.53, P < 0.001) and night (mean severity score 0.44 vs 0.51, P < 0.001) in week 1.


In patients with erosive esophagitis, lansoprazole was better than omeprazole for providing heartburn relief quickly.

*See Glossary.

†Information provided by author.

Source of funding: TAP Pharmaceutical Products.

For correspondence: Dr. J.E. Richter, The Cleveland Clinic Foundation, Cleveland, OH, USA. E-mail


Although proton-pump inhibitors (PPIs) may differ in pharmacokinetic profiles, all are efficacious in the treatment of erosive esophagitis. In a recent meta-analysis on the efficacy of different PPIs for the treatment of acute gastroesophageal reflux disease (1), no difference was found in rates of resolution of heartburn, ulcer healing, and relapse of symptoms when compared with placebo. These results are in accord with the general clinical experience with these drugs. Despite this finding, a competitive billion-dollar pharmaceutical market fuels studies designed to directly compare the efficacy and pharmacokinetic profiles of various PPIs, with the resulting small differences being promoted to persuade physicians to change their prescription habits in favor of a particular drug.

In this head-to-head comparison of lansoprazole with omeprazole, Richter and colleagues found lansoprazole to be more effective than omeprazole in eliminating heartburn after 1 dose as well as after 8 weeks of treatment. The authors suggest that this finding may be explained by the greater bioavailability of lansoprazole.

The authors are to be congratulated on putting together a large, well-designed, and well-executed study. However, are the results important? Although statistically significant, the differences between the 2 PPIs (especially beyond the 1st wk) are clinically trivial: For instance, does it really matter if 56% of the lansoprazole group are heartburn-free during the first 3 days compared with 49% of the omeprazole group when the average heartburn severity for both groups is < 1 (mild) on a scale of 0 to 4? Or that sustained heartburn relief is obtained in 53% of the lansoprazole group compared with 51% of the omeprazole group? In fact, this study probably reinforces the argument that differences between the current generation of PPIs are irrelevant in today’s health care environment in which the direct cost to the patient or the insurance plan, or both, has become the main factor in the PPI decision tree.

W. A. Hoogerwerf, MD
University of Texas Medical Branch
Galveston, Texas, USA

P. Jay Pasricha, MD
University of Texas Medical Branch
Galveston, Texas, USA


1. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther. 2001;23:998-1017. [PubMed ID: 11519776]